Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
.
2017 Jul 1;28(suppl_4):iv62-iv71.
doi: 10.1093/annonc/mdx223.
Authors
M Dreyling
1
,
E Campo
2
,
O Hermine
3
,
M Jerkeman
4
,
S Le Gouill
5
,
S Rule
6
,
O Shpilberg
7
,
J Walewski
8
,
M Ladetto
9
;
ESMO Guidelines Committee
Affiliations
1
Department of Medicine III, University Hospital - LMU Munich, Munich, Germany.
2
Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
3
Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France.
4
Department of Hematology, University Lund, Lund, Sweden.
5
CHU de Nantes, Service d'Hématologie Clinique, Université de Nantes, Nantes, France.
6
Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK.
7
Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel.
8
Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland.
9
Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
PMID:
28881919
DOI:
10.1093/annonc/mdx223
No abstract available
Publication types
Practice Guideline
MeSH terms
Follow-Up Studies
Humans
Lymphoma, Mantle-Cell / diagnosis*
Lymphoma, Mantle-Cell / genetics
Lymphoma, Mantle-Cell / pathology
Lymphoma, Mantle-Cell / therapy*
Medical Oncology / standards*